Article
Biochemistry & Molecular Biology
Nizar J. Bahlis, Caitlin L. Costello, Noopur S. Raje, Moshe Y. Levy, Bhagirathbhai Dholaria, Melhem Solh, Michael H. Tomasson, Michael A. Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M. Chan, Suzanne Trudel, Andrzej Jakubowiak, Cristina Gasparetto, Michael P. Chu, Andrew Dalovisio, Michael Sebag, Alexander M. Lesokhin
Summary: In the first-in-human trial of elranatamab, patients with refractory or relapsed multiple myeloma who received the bispecific antibody against BCMA and CD3 experienced no dose-limiting toxicities during dose escalation, and the agent showed promising clinical efficacy.
Article
Biochemistry & Molecular Biology
Alexander H. Lesokhin, Michael Tomasson, Bertrand J. Arnulf, Nizar Bahlis, H. Miles Prince, Ruben Niesvizky, Paula Rodriguez-Otero, Joaquin Martinez-Lopez, Guenther Koehne, Cyrille Touzeau, Yogesh Jethava, Hang Quach, Julien Depaus, Hisayuki Yokoyama, Afshin Eli A. Gabayan, Don K. Stevens, Ajay Nooka, Salomon Manier, Noopur Raje, Shinsuke Iida, Marc-Steffen Raab, Emma Searle, Eric T. Leip, Sharon Sullivan, Umberto Conte, Mohamed Elmeliegy, Akos Czibere, Andrea Viqueira, Mohamad Mohty
Summary: Elranatamab, a humanized BCMA-CD3 bispecific antibody, showed promising efficacy in patients with relapsed or refractory multiple myeloma. The primary endpoint of confirmed objective response rate was met with an ORR of 61.0%. With a median follow-up of 14.7 months, the duration of response, progression-free survival, and overall survival have not been reached. Adverse events were manageable, and switching to biweekly dosing improved safety without compromising efficacy.
Article
Oncology
Chenggong Li, Jia Xu, Wenjing Luo, Danying Liao, Wei Xie, Qiuzhe Wei, Yinqiang Zhang, Xindi Wang, Zhuolin Wu, Yun Kang, Jin'e Zheng, Wei Xiong, Jun Deng, Yu Hu, Heng Mei
Summary: Bispecific CS1-BCMA CAR-T cells showed clinical activity and good safety profiles in patients with relapsed or refractory multiple myeloma.
Article
Oncology
Xiaoyan Qu, Gang An, Weiwei Sui, Tingyu Wang, Xian Zhang, Junfang Yang, Yan Zhang, Lu Zhang, Dan Zhu, Jiaqi Huang, Shigui Zhu, Xin Yao, Jing Li, Chengxiao Zheng, Kevin Zhu, Yutian Wei, Xiaoteng Lv, Liping Lan, Yihong Yao, Daobin Zhou, Peihua Lu, Lugui Qiu, Jianyong Li
Summary: The study demonstrated that C-CAR088 has a good safety profile and high antitumor activity in patients with RRMM, making it a promising treatment option.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Hematology
Ying Wang, Chunrui Li, Jieyun Xia, Ping Li, Jiang Cao, Bin Pan, Xu Tan, Hujun Li, Kunming Qi, Xiangmin Wang, Ming Shi, Guangjun Jing, Zhiling Yan, Hai Cheng, Feng Zhu, Haiying Sun, Wei Sang, Depeng Li, Xi Zhang, Zhenyu Li, Junnian Zheng, Aibin Liang, Jianfeng Zhou, Kailin Xu
Summary: The study revealed a significant and lasting humoral immune deficiency, especially for IgA, in patients with relapsed/refractory MM who received anti-BCMA CAR T-cell therapy.
Review
Medicine, General & Internal
Razwana Khanam, Beth Faiman, Saba Batool, Mohammed Musa Najmuddin, Rana Usman, Kiran Kuriakose, Arooj Ahmed, Mohammad Ebad Ur Rehman, Zinath Roksana, Zain Syed, Faiz Anwer, Shahzad Raza
Summary: Anti-B-cell maturation antigen therapies have shown promising results in relapsed refractory multiple myeloma, but severe side effects pose a risk to patients. This review focuses on the most common complications post-BCMA therapy, discussing risk factors, pathogenesis, clinical features, and prevention and treatment strategies. FDA-approved agents for adult RRMM patients were analyzed to outline stepwise management of complications.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Barry Paul, Cesar Rodriguez, Saad Z. Usmani
Summary: Targeting B cell maturation antigen (BCMA) has emerged as an effective strategy for treating relapsed and refractory myeloma. Several mechanisms, including antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T cells and natural killer cells, are being investigated for targeting BCMA. Early phase clinical trials have shown unprecedented response rates in highly refractory myeloma patients, but there are still many questions to be answered.
Article
Immunology
Yasa Gul Mutlu, Sureyya Yigit Kaya, Senem Maral, Elif Melek, Zafer Baslar, Leylagul Kaynar, Omur Gokmen Sevindik
Summary: Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication, and there are limited treatment options available. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown success in treating MM, but their efficacy in treating CNS involvement is still uncertain. This case presents a successful treatment of CNS-involved MM using Elranatamab, a humanized bispecific antibody.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, Research & Experimental
Xiaohui Zhang, Chenxi Ouyang, Guofeng Sun, Hongfeng Liu, Junyuan Qi, Xiaohui Suo
Summary: The present study demonstrates that anti-BCMA CAR-T cell therapy shows promising efficacy and controllable adverse effects in the treatment of relapsed or refractory multiple myeloma and extramedullary invasion.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2023)
Article
Medicine, General & Internal
Philippe Moreau, Alfred L. Garfall, Niels W. C. J. van de Donk, Hareth Nahi, Jesus F. San-Miguel, Albert Oriol, Ajay K. Nooka, Thomas Martin, Laura Rosinol, Ajai Chari, Lionel Karlin, Lotfi Benboubker, Maria-Victoria Mateos, Nizar Bahlis, Rakesh Popat, Britta Besemer, Joaquin Martinez-Lopez, Surbhi Sidana, Michel Delforge, Lixia Pei, Danielle Trancucci, Raluca Verona, Suzette Girgis, Shun X. W. Lin, Yunsi Olyslager, Mindy Jaffe, Clarissa Uhlar, Tara Stephenson, Rian Van Rampelbergh, Arnob Banerjee, Jenna D. Goldberg, Rachel Kobos, Amrita Krishnan, Saad Z. Usmani
Summary: Teclistamab demonstrated promising efficacy in patients with relapsed or refractory multiple myeloma, leading to high rates of deep and durable response. Common adverse events included cytokine release syndrome, cytopenias, and infections, with toxic effects mostly grade 1 or 2.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Haobin Deng, Meijing Liu, Ting Yuan, Huan Zhang, Rui Cui, Jingyi Li, Jijun Yuan, Xiaofang Wang, Yafei Wang, Qi Deng
Summary: This study observed the efficacy and safety of humanized anti-BCMA chimeric antigen receptor (CAR) T cell therapy in relapsed/refractory multiple myeloma patients with and without extramedullary disease. It was found that patients with extramedullary disease benefited in the short term from the therapy, although they experienced higher grades of cytokine release syndrome and immune effector cell-associated neurotoxic syndrome.
FRONTIERS IN IMMUNOLOGY
(2021)
Editorial Material
Medicine, General & Internal
Sham Mailankody, Ola Landgren
Summary: BCMA has been recognized as a prognostic marker in multiple myeloma for over two decades, and is now a major target for various treatments including CAR T cells, antibody drug conjugates, and bispecific antibodies. The rapid translation from preclinical studies to FDA-approved treatments demonstrates significant success in the field.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Oncology
James F. Wu, Binod Dhakal
Summary: The use of BCMA as a therapeutic target has shown remarkable results in the treatment of RRMM, leading to the approval of BCMA-targeted CAR-T cell therapies. Researchers are now focusing on building upon and improving these therapies. This article discusses long-term data, a phase 3 trial supporting their use in earlier lines, and new manufacturing platforms to decrease treatment time. Additionally, it highlights five key abstracts from the 2023 ASCO Annual Meeting showcasing exciting updates in BCMA-directed CAR-T cell therapies in RRMM.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Di Wang, Haiying Fu, Yimei Que, Haitao Ruan, Menglei Xu, Xiaolu Long, Qiuxia Yu, Chunhui Li, Zhe Li, Songbai Cai, Wei Chen, Cong Sun, Guang Hu, Shuai Wang, Donggou He, Jianming Mei, Wen Wang, Chunrui Li
Summary: In this study, the combination of Selinexor and CT103A showed preliminary synergistic effect in treating relapsed/refractory extramedullary myeloma. Both patients achieved stringent complete remission after the treatment, with good tolerance to the combination therapy. Additionally, low dose of Selinexor was found to enhance CAR-T cell function in vitro by upregulating BCMA expression on plasma cell lines.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Letter
Oncology
Quan Ren, Yingling Zu, Hongchang Su, Qiumei Lu, Bin Xiang, Yanping Luo, Jishuai Zhang, Yongping Song
Summary: Researchers synthesized four single VHH-directed anti-BCMA CAR-NK cells and improved their cytotoxicity by altering intracellular and hinge regions, as well as ectopically expressing IL-15. In vitro and in vivo experiments demonstrated that BCMA-CD28-IL15 CAR-NK cells exhibited strong killing ability and cytokine secretion against BCMA+ tumor cells, indicating their potential application in multiple myeloma treatment.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2023)
